13
Jan
2025
Moving from Biotech to Nature
Everything started with my love for animals. I studied biology and journalism at the University of Warsaw — science because I loved nature, and journalism because I believed it would be my escape from the confines of post-communist Poland. I yearned to explore the world with friends, and did a variety of jobs – waiting tables, gorilla zookeeping, blackjack dealing... Read More
9
Jan
2025
Novo, Variant Benefit Sharing Win, Verdiva Joins Obesity Fray & Maze Eyes IPO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Jan
2025
Australia’s Little-Known Biotech Advantages and Risks
Most US biotech entrepreneurs and investors don’t consider Australia a thriving global hub. But there are compelling reasons to take another look at what’s happening there now. Australia has become more attractive based on its willingness to allow fast, affordable clinical trials to help early-stage developers gather human data on new drug candidates. That low-cost, high-speed, high-quality early development capability... Read More
8
Jan
2025
How the US Can Continue to Lead As China Rises
China made its intentions known 10 years ago. In the “Made in China 2025” plan, released in 2015, the government identified biopharmaceuticals as one of the industries where it sought a world leadership position. The investment has paid off. By making biotech a top priority, the China biotech ecosystem is now thriving. As we enter 2025, the strength of China’s... Read More
6
Jan
2025
AI Needs Natural Language to Give Structure to Biology
The word of the day, at least in the AI for Biology community, is foundation models. Everyone wants bigger data on more things to throw into bigger models. Virtual cell models will enable us to predict how cell states will change in response to chemical perturbations. Protein language models will enable us to identify better enzymes for degrading plastics or... Read More
2
Jan
2025
Investing in Biotech: David Schenkein on The Long Run
David Schenkein is today’s guest on The Long Run. David is a general partner with GV. It’s the non-strategic corporate venture firm formerly known as Google Ventures. GV is backed by a single limited partner, Alphabet, and has $10 billion in assets under management in 400 active portfolio companies working in tech and life sciences. In this conversation, we talk... Read More
19
Dec
2024
Vertex Pain Drug Fails, Puretech Delivers for IPF, Merck Dumps TIGIT, LAG3 Antibodies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Dec
2024
The Past, Present and Future of RNAi Therapies: Kevin Fitzgerald on The Long Run
Today’s guest on The Long Run is Kevin Fitzgerald. Kevin is the chief scientific officer of Cambridge, Mass.-based Alnylam Pharmaceuticals. He joined the company way back in 2005, when it was aspiring to create a new class of RNA interference medicines. These are sometimes referred to as “gene silencing” drugs. They are designed to shut down the production of disease-related... Read More
12
Dec
2024
ASH Recap, Dimension Captures $500M, & AbbVie’s New Parkinson’s Drug
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Dec
2024
Dimension Raises $500M to Seize the Tech-Driven Biology Future
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Dec
2024
ASH Highlights: Beam Base Editing, Novo’s Oral Pill Advance for Sickle Cell
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Dec
2024
Lilly Beats Novo, Amgen’s So-So Obesity Data & Atlas Stays Lean & Mean
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Dec
2024
Computational Techniques Are Driving a Tidal Shift in Therapeutic Protein Design
I recently attended the Molecular Machine Learning (MoML) Conference sponsored by the MIT Jameel Clinic, an institute focused on cutting-edge machine learning (ML) techniques in the life sciences. Computational approaches to drug discovery and development were the centerpiece of the symposium. Investor sentiment for ML-centric discovery biotechs has been turbulent recently, but researchers at MoML were widely and consistently enthusiastic.... Read More
4
Dec
2024
Versant, Novo-backed Antag Gets $84M for Weight Loss Drug with Combo Potential
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Nov
2024
What Should We Pay for a Good Death?
The intensive care unit in a hospital is a place where hope and despair whisper back and forth in the air. For Richard, the emotional seesaw was becoming all too familiar. This was his third ICU stay in a month, and the ninth brush with life and death from pulmonary arterial hypertension. No matter how hard the day was, he... Read More
26
Nov
2024
Meet the 2025 Timmerman Traverse for Damon Runyon Cancer Research Team
I’m excited to announce the 2025 Timmerman Traverse for Damon Runyon Cancer Research Foundation team. This group of 17 men and women are on a mission to raise more than $700,000 for the next generation of outstanding cancer researchers. In April, we’ll come together on the world-famous trek to Everest Base Camp, elevation 17,600 feet. We’re raising awareness for cancer... Read More
25
Nov
2024
How to Quit Smoking and Prevent Cancer: Jonathan Bricker on The Long Run
Today’s guest on The Long Run is Jonathan Bricker. Jonathan is a professor in the cancer prevention program that’s part of the Public Health Sciences Division at Fred Hutchinson Cancer Center in Seattle. This episode is a little different than most. Jonathan is a clinical psychologist by training. His research team focuses on how to use a combination of technology... Read More
24
Nov
2024
A Story of Hope For Kids With Rare Disease
As we head into Thanksgiving, I wanted to share a story that highlights the promise and possibility that can emerge from a devastating diagnosis, and emphasizes what can happen when industry, academia, and — especially — impassioned parents and advocates join forces. Consider the devasting rare genetic disease, spinal muscular atrophy, or SMA. According to Cure SMA, SMA is “a... Read More
21
Nov
2024
Dr. Oz to CMS, Amgen and Pfizer Get New CSOs, & SubQ Keytruda Arrives
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Nov
2024
Speaking Up for Science and Health. Even When Inconvenient
“By their fruits, ye shall know them” –Matthew 7:16 Immediately following the election of Donald Trump, a number of publications asked leaders of the biopharmaceutical industry and investment community to share their thoughts on how his likely policies and appointees to key positions of leadership will affect our industry. Many of these leaders counseled us to “wait and see” before making... Read More